Choosing Your Path in Systemic Lupus Erythematosus
From Patient Evaluations to New Targeted Therapies
Classification Criteria
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.
Aringer M, et al. Arthritis Rheumatol. 2019;71(9):1400-1412.
Disease Management Guidelines
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Fanouriakis A, et al. Ann Rheum Dis. 2019;78(6):736-745.
Patient Resources
American College of Rheumatology
Lupus Foundation of America
Lupus Research Alliance
Suggested Readings
Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Choi MY, et al. Ann Rheum Dis. 2022. [E-pub ahead of print.]
Association of a combination of healthy lifestyle behaviors with reduced risk of incident systemic lupus erythematosus.
Choi MY, et al. Arthritis Rheumatol. 2022;74(2):274-283.
Update οn the diagnosis and management of systemic lupus erythematosus.
Fanouriakis A, et al. Ann Rheum Dis. 2021;80(1):14-25.
Two-year, randomized, controlled trial of belimumab in lupus nephritis.
Furie R, et al. N Engl J Med. 2020;383(12):1117-1128.
Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries.
Izmirly PM, et al. Arthritis Rheumatol. 2021;73(6):991-996.
All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study.
Moghaddam B, et al. Rheumatology. 2021;61(1):367-376.
Trial of anifrolumab in active systemic lupus erythematosus.
Morand EF, et al. N Engl J Med. 2020;382(3):211-221.
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Rovin BH, et al. Lancet. 2021;397(10289):2070-2080.
SLE mortality remains disproportionately high, despite improvements over the last decade.
Singh RR, Yen EY. Lupus. 2018;27(10):1577-1581.
Relevant Resources
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Targeting Immune Dysregulation and Delivering Comprehensive Care
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Debates & Discussions on the Evolving Role of JAK Inhibitors
The Evolving Role of JAK Inhibitors
Unpacking the Evidence for Their Use Today and Tomorrow
Unlocking Novel Paths to Patient Care
The Increasing Role of JAK Inhibitors
Unlocking Novel Paths to Patient Care
New Pathways to Patient Management
A Focus on Clinical Evidence and Guideline Recommendations
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
